NASDAQ:FEMY Femasys (FEMY) Stock Price, News & Analysis → Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years (From Banyan Hill Publishing) (Ad) Free FEMY Stock Alerts $1.27 -0.06 (-4.51%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$1.21▼$1.3650-Day Range$1.23▼$2.2252-Week Range$0.25▼$4.75Volume136,817 shsAverage Volume328,432 shsMarket Capitalization$28.07 millionP/E RatioN/ADividend YieldN/APrice Target$11.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Femasys alerts: Email Address Femasys MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside792.4% Upside$11.33 Price TargetShort InterestHealthy5.84% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.88) to ($0.42) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.93 out of 5 starsMedical Sector382nd out of 913 stocksSurgical & Medical Instruments Industry47th out of 95 stocks 3.5 Analyst's Opinion Consensus RatingFemasys has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageFemasys has only been the subject of 3 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted5.84% of the float of Femasys has been sold short.Short Interest Ratio / Days to CoverFemasys has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Femasys has recently decreased by 31.61%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldFemasys does not currently pay a dividend.Dividend GrowthFemasys does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for FEMY. Previous Next 2.2 News and Social Media Coverage News SentimentFemasys has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.32 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Femasys this week, compared to 1 article on an average week.Search InterestOnly 5 people have searched for FEMY on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added Femasys to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Femasys insiders have not sold or bought any company stock.Percentage Held by Insiders16.39% of the stock of Femasys is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions65.27% of the stock of Femasys is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Femasys are expected to grow in the coming year, from ($0.88) to ($0.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Femasys is -1.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Femasys is -1.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFemasys has a P/B Ratio of 1.49. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressBiden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.See his shocking evidence in this new report About Femasys Stock (NASDAQ:FEMY)Femasys Inc., a biomedical company, develops novel solutions for women's healthcare market in the United States and internationally. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. In addition, the company provides non-surgical product technologies. It offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.Read More FEMY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FEMY Stock News HeadlinesApril 18, 2024 | finance.yahoo.comFemasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women’s Healthcare InitiativesApril 18, 2024 | globenewswire.comFemasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women's Healthcare InitiativesApril 27, 2024 | True Market Insiders (Ad)The “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…April 17, 2024 | msn.comFemasys (FEMY) Price Target Increased by 5.41% to 9.95March 31, 2024 | finance.yahoo.comFemasys Full Year 2023 Earnings: EPS Beats Expectations, Revenues LagMarch 28, 2024 | investorplace.comFEMY Stock Earnings: Femasys Beats EPS, Misses Revenue for Q4 2023March 28, 2024 | globenewswire.comFemasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate UpdateMarch 21, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Femasys (FEMY), BioNTech SE (BNTX)April 27, 2024 | True Market Insiders (Ad)The “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…March 21, 2024 | globenewswire.comFemasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment LandscapeMarch 21, 2024 | marketwatch.comFemasys Discloses Positive Data from FemaSeed TrialMarch 20, 2024 | finanznachrichten.deFemasys Inc.: Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed for the Treatment of InfertilityMarch 20, 2024 | markets.businessinsider.comFemasys Announces Positive Data For FemaSeed Trial To Enhance Fertilization In WomenMarch 20, 2024 | globenewswire.comFemasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of InfertilityMarch 13, 2024 | finance.yahoo.comFemasys to Participate in Fireside Chat to Discuss the Infertility Treatment Landscape on March 21, 2024March 9, 2024 | morningstar.comThinking about buying stock in Onespan, Avinger, Lithium Americas, Geron, or Femasys?March 6, 2024 | finanznachrichten.deFemasys Inc.: Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility SolutionMarch 6, 2024 | globenewswire.comFemasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility SolutionFebruary 28, 2024 | finanznachrichten.deFemasys Inc.: Femasys' FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVFFebruary 28, 2024 | finance.yahoo.comFemasys’ FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVFFebruary 28, 2024 | globenewswire.comFemasys' FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVFFebruary 24, 2024 | benzinga.comFemasys Stock (NASDAQ:FEMY), Short Interest ReportFebruary 12, 2024 | msn.comT2 Biosystems, Invivyd among healthcare moversFebruary 7, 2024 | msn.comFemasys Welcomes New Chief Commercial Officer Mr. SpectorJanuary 23, 2024 | finance.yahoo.comFemasys Inc. Begins FemBloc Pivotal Trial Enrollment at University of Utah, an Internationally Recognized Center in Obstetrics and GynecologyDecember 27, 2023 | benzinga.comFemasys Stock (NASDAQ:FEMY) Dividends: History, Yield and DatesDecember 15, 2023 | finance.yahoo.comFemasys Inc. Begins FemBloc Pivotal Trial Enrollment at Stanford MedicineSee More Headlines Receive FEMY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Femasys and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/28/2024Today4/26/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:FEMY CUSIPN/A CIK1339005 Webwww.femasys.com Phone770-500-3910FaxN/AEmployees32Year FoundedN/APrice Target and Rating Average Stock Price Target$11.33 High Stock Price Target$12.00 Low Stock Price Target$10.00 Potential Upside/Downside+792.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,250,000.00 Net Margins-1,329.10% Pretax Margin-1,328.64% Return on Equity-105.47% Return on Assets-80.50% Debt Debt-to-Equity Ratio0.24 Current Ratio7.59 Quick Ratio7.37 Sales & Book Value Annual Sales$1.07 million Price / Sales26.23 Cash FlowN/A Price / Cash FlowN/A Book Value$0.85 per share Price / Book1.49Miscellaneous Outstanding Shares22,100,000Free Float18,477,000Market Cap$28.07 million OptionableNot Optionable Beta-3.00 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMs. Kathy Lee-Sepsick M.B.A. (Age 55)Founder, President, CEO & Director Comp: $453.58kMr. Dov Elefant (Age 57)Chief Financial Officer Comp: $355.72kMr. Daniel Scott Currie (Age 60)COO, Senior VP & Secretary Comp: $352.55kMs. Mary An Merchant J.D.Ph.D., Vice President of Counsel & Intellectual PropertyDr. Jeffrey Marcus M.D.M.S., Chief Medical AdvisorMs. Christine Thomas (Age 51)Senior VP of Regulatory & Clinical Affairs Dr. James H. Liu M.D.Chief Medical OfficerMr. Richard SpectorChief Commercial OfficerMore ExecutivesKey CompetitorsNeuroOne Medical TechnologiesNASDAQ:NMTCSeaStar MedicalNASDAQ:ICUSpectral AINASDAQ:MDAIPrecision OpticsNASDAQ:POCIModular MedicalNASDAQ:MODDView All CompetitorsInstitutional OwnershipClear Creek Financial Management LLCBought 72,505 shares on 4/26/2024Ownership: 1.399%View All Institutional Transactions FEMY Stock Analysis - Frequently Asked Questions Should I buy or sell Femasys stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Femasys in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" FEMY shares. View FEMY analyst ratings or view top-rated stocks. What is Femasys' stock price target for 2024? 3 equities research analysts have issued twelve-month target prices for Femasys' stock. Their FEMY share price targets range from $10.00 to $12.00. On average, they anticipate the company's stock price to reach $11.33 in the next twelve months. This suggests a possible upside of 792.4% from the stock's current price. View analysts price targets for FEMY or view top-rated stocks among Wall Street analysts. How have FEMY shares performed in 2024? Femasys' stock was trading at $0.9750 at the beginning of 2024. Since then, FEMY shares have increased by 30.3% and is now trading at $1.27. View the best growth stocks for 2024 here. Are investors shorting Femasys? Femasys saw a drop in short interest in the month of April. As of April 15th, there was short interest totaling 1,190,000 shares, a drop of 31.6% from the March 31st total of 1,740,000 shares. Based on an average daily trading volume, of 720,300 shares, the days-to-cover ratio is currently 1.7 days. Currently, 5.8% of the shares of the company are short sold. View Femasys' Short Interest. When is Femasys' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our FEMY earnings forecast. How were Femasys' earnings last quarter? Femasys Inc. (NASDAQ:FEMY) issued its quarterly earnings results on Thursday, March, 28th. The company reported ($0.19) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.19). The company had revenue of $0.21 million for the quarter, compared to analyst estimates of $0.30 million. Femasys had a negative trailing twelve-month return on equity of 105.47% and a negative net margin of 1,329.10%. When did Femasys IPO? Femasys (FEMY) raised $35 million in an initial public offering (IPO) on Friday, June 18th 2021. The company issued 2,700,000 shares at $12.00-$14.00 per share. Chardan and JonesTrading acted as the underwriters for the IPO. Who are Femasys' major shareholders? Femasys' stock is owned by many different retail and institutional investors. Top institutional investors include Clear Creek Financial Management LLC (1.40%). View institutional ownership trends. How do I buy shares of Femasys? Shares of FEMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:FEMY) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersA.I. is a Tidal Wave - Here’s What to BuyChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Femasys Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
